<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962390</url>
  </required_header>
  <id_info>
    <org_study_id>AUS CT04</org_study_id>
    <nct_id>NCT00962390</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia</brief_title>
  <official_title>Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS 131 (S Equol) on Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ausio Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ausio Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of S-equol in men with
      benign prostatic hyperplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a phase 2a, randomized, double blind, multicenter, placebo controlled, parallel
      group, proof of concept study comparing the efficacy, safety, and acceptability of S-equol to
      placebo in patients with benign prostatic hyperplasia. The study objective is to examine a
      dose response of 3 dose levels of S equol versus placebo on prostate specific antigen
      concentrations in patients with benign prostatic hyperplasia. The safety of S-equol will be
      evaluated during the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline at Week 4 in Prostate Specific Antigen (PSA) Concentration.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Prostate specific antigen is considered to be the most sensitive measure of S-equol effects on the prostate, due to the expected effects of S-equol on the androgen receptor axis. In this proof-of-concept study, a population of 124 male subjects was estimated to achieve approximately 104 completed subjects (based on an estimated drop-out rate of 15%) to examine the dose-response compared to placebo. A sample size of 26 subjects in each treatment arm was considered to be adequate to observe a trend in this proof-of-concept study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Prostate Volume From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Prostate size as measured by prostate volume as assessed by transrectal ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Qmax From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorical Change in Qmax From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Qmax From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Void Volume From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Post-Void Residual Volume From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in in Dihydrotestosterone Concentration From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Luteinizing Hormone Concentration From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Testosterone Concentration From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Assessment of Nocturia at Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Participants were asked to rate their change in nocturia (number of times you wake from sleep to urinate) since the Baseline Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigators Assessment of Nocturia at Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Investigators were asked to rate participant's change in nocturia since the Baseline Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in I-PSS Total Score From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>The International Prostate Symptom Score (I-PSS) is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of 6 answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic). The first seven questions of the I-PSS are identical to the questions appearing on the American Urological Association (AUA) Symptom Index which currently categorizes symptoms as follows: Mild (symptom score less than of equal to 7); Moderate (symptom score range 8-19); and Severe (symptom score range 20-35). A reduction in I-PSS Total Score is consistent with improvement in symptoms of BPH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAN Prostate Symptom Scale From Baseline at Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>The questionnaire is made up of two kinds of questions: intensity of a symptom and bothersomeness of a symptom. Prostate symptoms are addressed in questions 1 - 12 and sexual function in questions 13 - 15. Patients indicate how intense/frequent (scoring 0, 1, 2, or 3; where 0 represents the best case and 3 the worst case) and how bothersome the symptom (scoring 0, 1, 2, or 3; where 0 is 'not at all' and 3 is 'very much'). DAN-PSS total and DAN-PSS total sexual function score were calculated by multiplying the frequency score by the trouble score of each symptom, and then adding the resulting figures. The possible values of DAN-PSS total ranged from 0 to 108 and of DAN-PSS total sexual function score ranged from 0 to 27. A reduction in DAN-PSS total and/or sexual function score is consistent with improved BPH symptoms/sexual functioning.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>150mg S-equol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg S-equol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg S-equol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-equol</intervention_name>
    <description>10mg S-equol 50mg S-equol, &amp; 150mg S-equol</description>
    <arm_group_label>150mg S-equol</arm_group_label>
    <arm_group_label>50mg S-equol</arm_group_label>
    <arm_group_label>10 mg S-equol</arm_group_label>
    <other_name>AUS-131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is male &gt; 50 years of age at Screening.

          -  Has a normal digital rectal exam with the exception of prostate enlargement.

          -  Has suffered from symptoms of BPH for at least the 6 months before Screening.

          -  Has a prostate volume ≥ 20 mL and ≤ 70 mL as assessed by ultrasound.

          -  Has a serum PSA concentration &gt; 1.5 ng/mL and ≤ 10 ng/mL at Screening.

          -  Has an IPSS &gt; 13 at Screening and Baseline.

          -  Has a Qmax &gt; 5 cc/sec and &lt; 15 cc/sec with a voided volume ≥ 125 cc at Screening (and
             Baseline, if applicable).

        Exclusion Criteria:

          -  Has a known history of allergic reaction or clinically significant intolerance to
             ingredients of the study drug.

          -  Neurogenic bladder dysfunction.

          -  Has bladder neck contracture or urethral stricture.

          -  Has acute or chronic prostatitis or urinary tract infection.

          -  Has, or has a history of, prostate cancer or carcinoma of the prostate suspected on
             digital rectal exam or transrectal ultrasound, or has a serum PSA concentration &gt; 10
             ng/mL; patients with a PSA concentration &gt; 4 ng/mL and ≤ 10 ng/mL must have prostate
             cancer ruled out to the satisfaction of the investigator.

          -  Has a residual void volume &gt; 250 mL.

          -  Has any clinically significant unstable condition that, in the opinion of the
             investigator, could compromise the patient's welfare, ability to communicate with the
             study staff, or otherwise contraindicate study participation.

          -  Shows presence of any manifest premalignant or malignant disease except treated skin
             cancers (except melanoma).

          -  Has a history of smoking more than 5 cigarettes daily within the year before
             Screening.

          -  Has resting systolic blood pressure (BP) &gt; 160 mmHg or &lt; 90 mmHg, or diastolic BP &gt; 90
             mmHg or &lt; 60 mmHg at Screening.

          -  Has bladder stones as detected by ultrasound.

          -  Has hematuria of unknown etiology.

          -  Had previous prostate surgery or other invasive treatment for BPH.

          -  Had prior radiation to the pelvis.

          -  Has Parkinson's disease or multiple sclerosis.

          -  Had stroke or myocardial infarction within 5 months before Baseline.

          -  Has abnormal screening electrocardiogram (ECG) or unstable angina or severe congestive
             heart failure.

          -  Has active liver disease renal insufficiency with creatinine &gt; 1.7 mg/dL, or
             clinically significant abnormal hemoglobin, white blood cell count, or platelet count.

          -  Has a history of postural hypotension or has a fall in systolic BP &gt; 20 mm Hg after 2
             minutes in a standing position.

          -  Received alpha blocker therapy within 28 days before Baseline.

          -  Received androgens, anti androgens, 5 alpha reductase inhibitors, or luteinizing
             hormone releasing hormone (LHRH) analogs within 3 months before Baseline.

          -  Received tricyclic antidepressants or plant extracts (e.g., saw palmetto) within 1
             month before Baseline.

          -  Received sedating antihistamines, sympathomimetics, or anticholinergics within 1 week
             before Baseline.

          -  Has initiated new use (i.e., within the past 4 weeks before Screening) or otherwise
             are not on stable doses of phosphodiesterase 5 inhibitors during the 4 weeks before
             Screening.

          -  Has known or suspected history of alcoholism or drug abuse or misuse within the last 5
             years.

          -  Is considered by the investigator, for any reason (including, but not limited to, the
             risks described as precautions, warnings, and contraindications in the current version
             of the Clinical Investigator's Brochure for AUS 131 [S equol]), to be an unsuitable
             candidate to receive the study drug.

          -  Has tested positive on the urine drug screen.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Bergner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampa Bay Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Affiliated Research Center</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordon</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samved Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Medical College Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G S Medical College and KEM Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indraprastha Apollo Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V M Medical College and Safdarjung Hospital</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMS Hospital</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A J Hospital and Research Center</name>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inamdar Multispecialty Hospital</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruby Hall Clinic</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2009</study_first_submitted>
  <study_first_submitted_qc>August 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2009</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>April 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2017</results_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Equol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 4 centers in Australia, 10 centers in India, and 8 centers in the United States from February 2010 to August 2015. The first participant was enrolled in August 2010, and the last participant was enrolled in August 2015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>S-equol 10 mg BID</title>
          <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>S-equol 50 mg BID</title>
          <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>S-equol 150 mg BID</title>
          <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo BID</title>
          <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who took at least one (1) dose of investigational product were included in the baseline analysis population.</population>
      <group_list>
        <group group_id="B1">
          <title>S-equol 10 mg BID</title>
          <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>S-equol 50 mg BID</title>
          <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>S-equol 150 mg BID</title>
          <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Placebo BID</title>
          <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="29"/>
            <count group_id="B5" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="29"/>
                    <count group_id="B5" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="9.1"/>
                    <measurement group_id="B2" value="64.6" spread="6.5"/>
                    <measurement group_id="B3" value="63.1" spread="8.8"/>
                    <measurement group_id="B4" value="62.7" spread="7.7"/>
                    <measurement group_id="B5" value="63.4" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="29"/>
                    <count group_id="B5" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="29"/>
                    <count group_id="B5" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="29"/>
                    <count group_id="B5" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate specific antigen (PSA) concentration</title>
          <population>Participants who had taken at least one (1) dose of investigational product and had a baseline value of interest.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="29"/>
                    <count group_id="B5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.509" spread="2.241"/>
                    <measurement group_id="B2" value="3.308" spread="1.796"/>
                    <measurement group_id="B3" value="3.210" spread="1.075"/>
                    <measurement group_id="B4" value="3.514" spread="1.860"/>
                    <measurement group_id="B5" value="3.386" spread="1.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Volume</title>
          <population>Participants who had taken at least one (1) dose of investigational product and had a baseline value of interest.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="29"/>
                    <count group_id="B5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.46" spread="13.47"/>
                    <measurement group_id="B2" value="44.79" spread="14.27"/>
                    <measurement group_id="B3" value="40.83" spread="11.40"/>
                    <measurement group_id="B4" value="41.41" spread="11.39"/>
                    <measurement group_id="B5" value="42.61" spread="12.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Post Void Residual Urine Volume</title>
          <population>Participants who had taken at least one (1) dose of investigational product and had a baseline value of interest.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="29"/>
                    <count group_id="B5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.59" spread="60.45"/>
                    <measurement group_id="B2" value="62.00" spread="55.93"/>
                    <measurement group_id="B3" value="61.38" spread="60.37"/>
                    <measurement group_id="B4" value="89.07" spread="56.01"/>
                    <measurement group_id="B5" value="71.91" spread="58.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Qmax Result</title>
          <population>Participants who had taken at least one (1) dose of investigational product and had a baseline value of interest.</population>
          <units>mL/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="29"/>
                    <count group_id="B5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.22" spread="3.13"/>
                    <measurement group_id="B2" value="10.27" spread="3.29"/>
                    <measurement group_id="B3" value="11.17" spread="3.30"/>
                    <measurement group_id="B4" value="10.98" spread="3.59"/>
                    <measurement group_id="B5" value="10.66" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Void Volume</title>
          <population>Participants who had taken at least one (1) dose of investigational product and had a baseline value of interest.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="29"/>
                    <count group_id="B5" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229.21" spread="128.59"/>
                    <measurement group_id="B2" value="245.75" spread="111.49"/>
                    <measurement group_id="B3" value="243.54" spread="115.54"/>
                    <measurement group_id="B4" value="261.48" spread="86.07"/>
                    <measurement group_id="B5" value="245.14" spread="110.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dihydrotestosterone</title>
          <population>Participants who had taken at least one (1) dose of investigational product and had a baseline value of interest.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="27"/>
                    <count group_id="B5" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="496.2" spread="425.2"/>
                    <measurement group_id="B2" value="533.6" spread="388.5"/>
                    <measurement group_id="B3" value="534.7" spread="467.4"/>
                    <measurement group_id="B4" value="446.1" spread="185.5"/>
                    <measurement group_id="B5" value="502.6" spread="378.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Luteinizing Hormone</title>
          <population>Participants who had taken at least one (1) dose of investigational product and had a baseline value of interest.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="28"/>
                    <count group_id="B5" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="4.2"/>
                    <measurement group_id="B2" value="5.1" spread="2.5"/>
                    <measurement group_id="B3" value="6.5" spread="4.1"/>
                    <measurement group_id="B4" value="5.9" spread="2.8"/>
                    <measurement group_id="B5" value="5.7" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Testosterone, Total</title>
          <population>Participants who had taken at least one (1) dose of investigational product and had a baseline value of interest.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="26"/>
                    <count group_id="B4" value="28"/>
                    <count group_id="B5" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="442.6" spread="311.7"/>
                    <measurement group_id="B2" value="319.9" spread="248.0"/>
                    <measurement group_id="B3" value="340.6" spread="180.9"/>
                    <measurement group_id="B4" value="372.7" spread="202.0"/>
                    <measurement group_id="B5" value="369.5" spread="243.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total International Prostate Symptom Score (I-PSS)</title>
          <description>The I-PSS is based on the answers to 7 questions concerning urinary symptoms and one question concerning the quality of life. Each question concerning urinary symptoms allows the subject to choose 1 out of 6 answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can, therefore, range from 0 (asymptomatic) to 35 (very symptomatic).</description>
          <population>Participants who had taken at least one (1) dose of investigational product and had a baseline value of interest.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="28"/>
                    <count group_id="B5" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.11" spread="5.24"/>
                    <measurement group_id="B2" value="23.64" spread="4.57"/>
                    <measurement group_id="B3" value="21.50" spread="4.59"/>
                    <measurement group_id="B4" value="21.32" spread="5.21"/>
                    <measurement group_id="B5" value="21.89" spread="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Danish Prostatic Symptom Score (DAN-PSS-1)</title>
          <description>The DAN-PSS-1 is a self-administered quality-of-life questionnaire comprising 12 questions related to lower urinary tract symptoms (bladder storage and voiding function), and 3 questions related to sexual function (symptom score). All answers for symptom and bothersomeness were classified in a 4-ranked scale from 0 (absence of symptoms or no impact on daily life) to 3 (the maximum severity of symptoms or impact on daily life). A weighted score was then calculated to give a total score that ranged from 0 to 108, where higher scores represented worsening symptoms and bothersomeness.</description>
          <population>Participants who had taken at least one (1) dose of investigational product and had a baseline value of interest.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="29"/>
                    <count group_id="B4" value="29"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="10.9"/>
                    <measurement group_id="B2" value="33.5" spread="15.3"/>
                    <measurement group_id="B3" value="27.2" spread="15.5"/>
                    <measurement group_id="B4" value="31.1" spread="19.1"/>
                    <measurement group_id="B5" value="29.5" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Week 4 in Prostate Specific Antigen (PSA) Concentration.</title>
        <description>Prostate specific antigen is considered to be the most sensitive measure of S-equol effects on the prostate, due to the expected effects of S-equol on the androgen receptor axis. In this proof-of-concept study, a population of 124 male subjects was estimated to achieve approximately 104 completed subjects (based on an estimated drop-out rate of 15%) to examine the dose-response compared to placebo. A sample size of 26 subjects in each treatment arm was considered to be adequate to observe a trend in this proof-of-concept study.</description>
        <time_frame>4 weeks</time_frame>
        <population>All Participants who received at least 1 dose of study drug and who had a post-dose PSA assessment at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Week 4 in Prostate Specific Antigen (PSA) Concentration.</title>
          <description>Prostate specific antigen is considered to be the most sensitive measure of S-equol effects on the prostate, due to the expected effects of S-equol on the androgen receptor axis. In this proof-of-concept study, a population of 124 male subjects was estimated to achieve approximately 104 completed subjects (based on an estimated drop-out rate of 15%) to examine the dose-response compared to placebo. A sample size of 26 subjects in each treatment arm was considered to be adequate to observe a trend in this proof-of-concept study.</description>
          <population>All Participants who received at least 1 dose of study drug and who had a post-dose PSA assessment at Week 4.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.3"/>
                    <measurement group_id="O2" value="-0.1" spread="0.3"/>
                    <measurement group_id="O3" value="-0.3" spread="0.3"/>
                    <measurement group_id="O4" value="-0.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4678</p_value>
            <p_value_desc>Statistical testing was 2-sided and the 5% significant level was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA included Baseline as covariate and factors for treatment and site.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>S-equol treatment group minus placebo group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4892</p_value>
            <p_value_desc>Statistical testing was 2-sided and the 5% significant level was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA included Baseline as covariate and factors for treatment and site.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>S-equol treatment group minus placebo group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 4, Treatment Effect</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8185</p_value>
            <p_value_desc>Statistical testing was 2-sided and the 5% significant level was used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA included Baseline as covariate and factors for treatment and site.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>S-equol treatment group minus placebo group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Prostate Volume From Baseline at Week 4</title>
        <description>Prostate size as measured by prostate volume as assessed by transrectal ultrasound.</description>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Prostate Volume From Baseline at Week 4</title>
          <description>Prostate size as measured by prostate volume as assessed by transrectal ultrasound.</description>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.03" spread="12.10"/>
                    <measurement group_id="O2" value="45.53" spread="15.36"/>
                    <measurement group_id="O3" value="39.16" spread="10.67"/>
                    <measurement group_id="O4" value="39.73" spread="13.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.03" spread="5.28"/>
                    <measurement group_id="O2" value="-0.25" spread="8.29"/>
                    <measurement group_id="O3" value="-1.72" spread="7.31"/>
                    <measurement group_id="O4" value="-1.74" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Qmax From Baseline at Week 4</title>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Qmax From Baseline at Week 4</title>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>mL/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" spread="5.87"/>
                    <measurement group_id="O2" value="10.10" spread="5.41"/>
                    <measurement group_id="O3" value="14.40" spread="5.70"/>
                    <measurement group_id="O4" value="13.40" spread="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="4.74"/>
                    <measurement group_id="O2" value="-0.09" spread="6.13"/>
                    <measurement group_id="O3" value="2.49" spread="6.25"/>
                    <measurement group_id="O4" value="2.25" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorical Change in Qmax From Baseline at Week 4</title>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Categorical Change in Qmax From Baseline at Week 4</title>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Values, &lt;=2 mL/sec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Values, &gt;2 mL/sec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Qmax From Baseline at Week 4</title>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Qmax From Baseline at Week 4</title>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Values, &lt;=30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Values, &gt;30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Void Volume From Baseline at Week 4</title>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Void Volume From Baseline at Week 4</title>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.04" spread="124.23"/>
                    <measurement group_id="O2" value="191.50" spread="88.79"/>
                    <measurement group_id="O3" value="312.09" spread="187.12"/>
                    <measurement group_id="O4" value="266.32" spread="119.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="128.97"/>
                    <measurement group_id="O2" value="-58.00" spread="116.23"/>
                    <measurement group_id="O3" value="72.18" spread="154.08"/>
                    <measurement group_id="O4" value="7.46" spread="134.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Post-Void Residual Volume From Baseline at Week 4</title>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Post-Void Residual Volume From Baseline at Week 4</title>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.90" spread="96.73"/>
                    <measurement group_id="O2" value="83.54" spread="96.98"/>
                    <measurement group_id="O3" value="52.46" spread="68.14"/>
                    <measurement group_id="O4" value="85.90" spread="81.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" spread="93.12"/>
                    <measurement group_id="O2" value="17.08" spread="93.73"/>
                    <measurement group_id="O3" value="-18.22" spread="69.97"/>
                    <measurement group_id="O4" value="-6.28" spread="73.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in in Dihydrotestosterone Concentration From Baseline at Week 4</title>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in in Dihydrotestosterone Concentration From Baseline at Week 4</title>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Values</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584.7" spread="567.0"/>
                    <measurement group_id="O2" value="532.4" spread="483.1"/>
                    <measurement group_id="O3" value="616.6" spread="661.9"/>
                    <measurement group_id="O4" value="502.4" spread="434.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" spread="313.1"/>
                    <measurement group_id="O2" value="-6.2" spread="139.9"/>
                    <measurement group_id="O3" value="68.1" spread="488.9"/>
                    <measurement group_id="O4" value="-14.5" spread="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Luteinizing Hormone Concentration From Baseline at Week 4</title>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Luteinizing Hormone Concentration From Baseline at Week 4</title>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Values</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.6"/>
                    <measurement group_id="O2" value="6.0" spread="3.4"/>
                    <measurement group_id="O3" value="6.1" spread="4.1"/>
                    <measurement group_id="O4" value="5.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.2"/>
                    <measurement group_id="O2" value="1.1" spread="2.5"/>
                    <measurement group_id="O3" value="-0.3" spread="2.4"/>
                    <measurement group_id="O4" value="0.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Testosterone Concentration From Baseline at Week 4</title>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Testosterone Concentration From Baseline at Week 4</title>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Values</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449.9" spread="283.7"/>
                    <measurement group_id="O2" value="310.3" spread="204.2"/>
                    <measurement group_id="O3" value="314.0" spread="177.2"/>
                    <measurement group_id="O4" value="351.3" spread="176.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="116.4"/>
                    <measurement group_id="O2" value="-2.6" spread="173.8"/>
                    <measurement group_id="O3" value="3.7" spread="93.9"/>
                    <measurement group_id="O4" value="-34.4" spread="128.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Assessment of Nocturia at Week 4</title>
        <description>Participants were asked to rate their change in nocturia (number of times you wake from sleep to urinate) since the Baseline Visit.</description>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Assessment of Nocturia at Week 4</title>
          <description>Participants were asked to rate their change in nocturia (number of times you wake from sleep to urinate) since the Baseline Visit.</description>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>number of times to urinate at night</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2" upper_limit="7"/>
                    <measurement group_id="O4" value="3.0" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigators Assessment of Nocturia at Week 4</title>
        <description>Investigators were asked to rate participant's change in nocturia since the Baseline Visit.</description>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigators Assessment of Nocturia at Week 4</title>
          <description>Investigators were asked to rate participant's change in nocturia since the Baseline Visit.</description>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>number of times urinated at night</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O3" value="3.0" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O4" value="3.0" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in I-PSS Total Score From Baseline at Week 4</title>
        <description>The International Prostate Symptom Score (I-PSS) is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of 6 answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic). The first seven questions of the I-PSS are identical to the questions appearing on the American Urological Association (AUA) Symptom Index which currently categorizes symptoms as follows: Mild (symptom score less than of equal to 7); Moderate (symptom score range 8-19); and Severe (symptom score range 20-35). A reduction in I-PSS Total Score is consistent with improvement in symptoms of BPH.</description>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in I-PSS Total Score From Baseline at Week 4</title>
          <description>The International Prostate Symptom Score (I-PSS) is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of 6 answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic). The first seven questions of the I-PSS are identical to the questions appearing on the American Urological Association (AUA) Symptom Index which currently categorizes symptoms as follows: Mild (symptom score less than of equal to 7); Moderate (symptom score range 8-19); and Severe (symptom score range 20-35). A reduction in I-PSS Total Score is consistent with improvement in symptoms of BPH.</description>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Values</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.56" spread="5.35"/>
                    <measurement group_id="O2" value="17.46" spread="5.79"/>
                    <measurement group_id="O3" value="17.54" spread="6.96"/>
                    <measurement group_id="O4" value="15.07" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.81" spread="7.56"/>
                    <measurement group_id="O2" value="-6.18" spread="5.55"/>
                    <measurement group_id="O3" value="-4.15" spread="6.42"/>
                    <measurement group_id="O4" value="-5.96" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in DAN Prostate Symptom Scale From Baseline at Week 4</title>
        <description>The questionnaire is made up of two kinds of questions: intensity of a symptom and bothersomeness of a symptom. Prostate symptoms are addressed in questions 1 - 12 and sexual function in questions 13 - 15. Patients indicate how intense/frequent (scoring 0, 1, 2, or 3; where 0 represents the best case and 3 the worst case) and how bothersome the symptom (scoring 0, 1, 2, or 3; where 0 is 'not at all' and 3 is 'very much'). DAN-PSS total and DAN-PSS total sexual function score were calculated by multiplying the frequency score by the trouble score of each symptom, and then adding the resulting figures. The possible values of DAN-PSS total ranged from 0 to 108 and of DAN-PSS total sexual function score ranged from 0 to 27. A reduction in DAN-PSS total and/or sexual function score is consistent with improved BPH symptoms/sexual functioning.</description>
        <time_frame>4 weeks</time_frame>
        <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>S-equol 10 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>S-equol 50 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>S-equol 150 mg BID</title>
            <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in DAN Prostate Symptom Scale From Baseline at Week 4</title>
          <description>The questionnaire is made up of two kinds of questions: intensity of a symptom and bothersomeness of a symptom. Prostate symptoms are addressed in questions 1 - 12 and sexual function in questions 13 - 15. Patients indicate how intense/frequent (scoring 0, 1, 2, or 3; where 0 represents the best case and 3 the worst case) and how bothersome the symptom (scoring 0, 1, 2, or 3; where 0 is 'not at all' and 3 is 'very much'). DAN-PSS total and DAN-PSS total sexual function score were calculated by multiplying the frequency score by the trouble score of each symptom, and then adding the resulting figures. The possible values of DAN-PSS total ranged from 0 to 108 and of DAN-PSS total sexual function score ranged from 0 to 27. A reduction in DAN-PSS total and/or sexual function score is consistent with improved BPH symptoms/sexual functioning.</description>
          <population>All randomized subjects who received at least 1 dose of investigational product starting at Baseline, and who had at least 1 post-dose assessment of interest.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score, Week 4 Values</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7" spread="10.9"/>
                    <measurement group_id="O2" value="22.1" spread="14.9"/>
                    <measurement group_id="O3" value="22.7" spread="14.6"/>
                    <measurement group_id="O4" value="20.3" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score, Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="12.9"/>
                    <measurement group_id="O2" value="-11.5" spread="15.4"/>
                    <measurement group_id="O3" value="-4.7" spread="12.0"/>
                    <measurement group_id="O4" value="-10.0" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Function Score, Week 4 Values</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="3.1"/>
                    <measurement group_id="O2" value="4.2" spread="5.4"/>
                    <measurement group_id="O3" value="5.6" spread="3.8"/>
                    <measurement group_id="O4" value="4.7" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Function Score, Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.6"/>
                    <measurement group_id="O2" value="0.2" spread="2.9"/>
                    <measurement group_id="O3" value="-1.2" spread="4.7"/>
                    <measurement group_id="O4" value="0.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from the time of signing of the ICF through the Follow-up Visit (Visit 6) or Early Termination Visit (whichever occurred first), up to Day 56±2 days.</time_frame>
      <desc>The investigator monitored and/or asked about or evaluated adverse events (AEs) using non-leading questions at each visit or evaluation. The occurrence of all AEs were documented in the Adverse Event Case Report Form.</desc>
      <group_list>
        <group group_id="E1">
          <title>S-equol 10 mg BID</title>
          <description>Experimental: S-equol
Participants received S-equol 10 mg capsule orally twice daily (20 mg total daily dose) for 4 weeks.
At-risk Participants were subjects who received at least one dose of S-at any time during the study.</description>
        </group>
        <group group_id="E2">
          <title>S-equol 50 mg BID</title>
          <description>Experimental: S-equol
Participants received S-equol 50 mg capsule orally twice daily (100 mg total daily dose) for 4 weeks.
At-risk Participants were subjects who received at least one dose of S-at any time during the study.</description>
        </group>
        <group group_id="E3">
          <title>S-equol 150 mg BID</title>
          <description>Experimental: S-equol
Participants received S-equol 150 mg capsule orally twice daily (300 mg total daily dose) for 4 weeks.
At-risk Participants were subjects who received at least one dose of S-at any time during the study.</description>
        </group>
        <group group_id="E4">
          <title>Placebo BID</title>
          <description>Placebo Comparator: Placebo
Participants received S-equol placebo capsule matching S-equol orally twice daily for 4 weeks.
At-risk Participants were subjects who received at least one dose of S-at any time during the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Gastro-oesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Paraesthesia of genital male</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rick Schwen, PhD, DABT, RAC / Vice President of Regulatory Affairs</name_or_title>
      <organization>Ausio Pharmaceuticals, LLC</organization>
      <phone>513-731-0222</phone>
      <email>rick@ausiopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

